Cargando…
Altered profiles of circulating cytokines in chronic liver diseases (NAFLD/HCC): Impact of the PNPLA3 ( I148M ) risk allele
BACKGROUND: Individuals carrying the risk variant p.I148M of patatin-like phospholipase domain-containing protein 3 (PNPLA3) have a higher susceptibility to fatty liver diseases and associated complications, including HCC, a cancer closely linked to chronic inflammation. Here, we assessed circulatin...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667005/ https://www.ncbi.nlm.nih.gov/pubmed/38015590 http://dx.doi.org/10.1097/HC9.0000000000000306 |
_version_ | 1785149004442501120 |
---|---|
author | Kirchmeyer, Mélanie Gaigneaux, Anthoula Servais, Florence A. Arslanow, Anita Casper, Markus Krawczyk, Marcin Lammert, Frank Behrmann, Iris |
author_facet | Kirchmeyer, Mélanie Gaigneaux, Anthoula Servais, Florence A. Arslanow, Anita Casper, Markus Krawczyk, Marcin Lammert, Frank Behrmann, Iris |
author_sort | Kirchmeyer, Mélanie |
collection | PubMed |
description | BACKGROUND: Individuals carrying the risk variant p.I148M of patatin-like phospholipase domain-containing protein 3 (PNPLA3) have a higher susceptibility to fatty liver diseases and associated complications, including HCC, a cancer closely linked to chronic inflammation. Here, we assessed circulating cytokine profiles for patients with chronic liver diseases genotyped for PNPLA3. METHODS: Serum concentrations of 22 cytokines were measured by multiplex sandwich-ELISA. The cohort comprised 123 individuals: 67 patients with NAFLD without cirrhosis (57 steatosis, 10 NASH), 24 patients with NAFLD with cirrhosis, 21 patients with HCC (15 cirrhosis), and 11 healthy controls. Receiver operator characteristic analyses were performed to assess the suitability of the cytokine profiles for the prediction of steatosis, cirrhosis, and HCC. RESULTS: HGF, IL-6, and IL-8 levels were increased in patients, with ∼2-fold higher levels in patients with cirrhosis versus healthy, while platelet derived growth factor-BB (PDGF-BB) and regulated on activation, normal T cell expressed and secreted (RANTES) showed lower concentrations compared to controls. Migration inhibitory factor and monocyte chemoattractant protein-1 (MCP-1) were found at higher levels in NAFLD samples (maximum: NAFLD-cirrhosis) versus healthy controls and HCC samples. In receiver operator characteristic analyses, migration inhibitory factor, IL-8, IL-6, and monocyte chemoattractant protein-1 yielded high sensitivity scores for predicting noncirrhotic NAFLD (vs. healthy). The top combination to predict cirrhosis was HGF plus PDGF-BB. Migration inhibitory factor performed best to discriminate HCC from NAFLD; the addition of monokine induced gamma (MIG), RANTES, IL-4, macrophage colony-stimulating factor (M-CSF), or IL-17A as second parameters further increased the AUC values (> 0.9). No significant impact of the PNPLA3 ( I148M ) allele on cytokine levels was observed in this cohort. CONCLUSIONS: Cytokines have biomarker potential in patients with fatty liver, possibly suited for early HCC detection in patients with fatty liver. Patients carrying the PNPLA3 risk allele did not present significantly different levels of circulating cytokines. |
format | Online Article Text |
id | pubmed-10667005 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-106670052023-11-22 Altered profiles of circulating cytokines in chronic liver diseases (NAFLD/HCC): Impact of the PNPLA3 ( I148M ) risk allele Kirchmeyer, Mélanie Gaigneaux, Anthoula Servais, Florence A. Arslanow, Anita Casper, Markus Krawczyk, Marcin Lammert, Frank Behrmann, Iris Hepatol Commun Original Article BACKGROUND: Individuals carrying the risk variant p.I148M of patatin-like phospholipase domain-containing protein 3 (PNPLA3) have a higher susceptibility to fatty liver diseases and associated complications, including HCC, a cancer closely linked to chronic inflammation. Here, we assessed circulating cytokine profiles for patients with chronic liver diseases genotyped for PNPLA3. METHODS: Serum concentrations of 22 cytokines were measured by multiplex sandwich-ELISA. The cohort comprised 123 individuals: 67 patients with NAFLD without cirrhosis (57 steatosis, 10 NASH), 24 patients with NAFLD with cirrhosis, 21 patients with HCC (15 cirrhosis), and 11 healthy controls. Receiver operator characteristic analyses were performed to assess the suitability of the cytokine profiles for the prediction of steatosis, cirrhosis, and HCC. RESULTS: HGF, IL-6, and IL-8 levels were increased in patients, with ∼2-fold higher levels in patients with cirrhosis versus healthy, while platelet derived growth factor-BB (PDGF-BB) and regulated on activation, normal T cell expressed and secreted (RANTES) showed lower concentrations compared to controls. Migration inhibitory factor and monocyte chemoattractant protein-1 (MCP-1) were found at higher levels in NAFLD samples (maximum: NAFLD-cirrhosis) versus healthy controls and HCC samples. In receiver operator characteristic analyses, migration inhibitory factor, IL-8, IL-6, and monocyte chemoattractant protein-1 yielded high sensitivity scores for predicting noncirrhotic NAFLD (vs. healthy). The top combination to predict cirrhosis was HGF plus PDGF-BB. Migration inhibitory factor performed best to discriminate HCC from NAFLD; the addition of monokine induced gamma (MIG), RANTES, IL-4, macrophage colony-stimulating factor (M-CSF), or IL-17A as second parameters further increased the AUC values (> 0.9). No significant impact of the PNPLA3 ( I148M ) allele on cytokine levels was observed in this cohort. CONCLUSIONS: Cytokines have biomarker potential in patients with fatty liver, possibly suited for early HCC detection in patients with fatty liver. Patients carrying the PNPLA3 risk allele did not present significantly different levels of circulating cytokines. Lippincott Williams & Wilkins 2023-11-22 /pmc/articles/PMC10667005/ /pubmed/38015590 http://dx.doi.org/10.1097/HC9.0000000000000306 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (https://creativecommons.org/licenses/by/4.0/) (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) |
spellingShingle | Original Article Kirchmeyer, Mélanie Gaigneaux, Anthoula Servais, Florence A. Arslanow, Anita Casper, Markus Krawczyk, Marcin Lammert, Frank Behrmann, Iris Altered profiles of circulating cytokines in chronic liver diseases (NAFLD/HCC): Impact of the PNPLA3 ( I148M ) risk allele |
title | Altered profiles of circulating cytokines in chronic liver diseases (NAFLD/HCC): Impact of the PNPLA3
(
I148M
) risk allele |
title_full | Altered profiles of circulating cytokines in chronic liver diseases (NAFLD/HCC): Impact of the PNPLA3
(
I148M
) risk allele |
title_fullStr | Altered profiles of circulating cytokines in chronic liver diseases (NAFLD/HCC): Impact of the PNPLA3
(
I148M
) risk allele |
title_full_unstemmed | Altered profiles of circulating cytokines in chronic liver diseases (NAFLD/HCC): Impact of the PNPLA3
(
I148M
) risk allele |
title_short | Altered profiles of circulating cytokines in chronic liver diseases (NAFLD/HCC): Impact of the PNPLA3
(
I148M
) risk allele |
title_sort | altered profiles of circulating cytokines in chronic liver diseases (nafld/hcc): impact of the pnpla3
(
i148m
) risk allele |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667005/ https://www.ncbi.nlm.nih.gov/pubmed/38015590 http://dx.doi.org/10.1097/HC9.0000000000000306 |
work_keys_str_mv | AT kirchmeyermelanie alteredprofilesofcirculatingcytokinesinchronicliverdiseasesnafldhccimpactofthepnpla3i148mriskallele AT gaigneauxanthoula alteredprofilesofcirculatingcytokinesinchronicliverdiseasesnafldhccimpactofthepnpla3i148mriskallele AT servaisflorencea alteredprofilesofcirculatingcytokinesinchronicliverdiseasesnafldhccimpactofthepnpla3i148mriskallele AT arslanowanita alteredprofilesofcirculatingcytokinesinchronicliverdiseasesnafldhccimpactofthepnpla3i148mriskallele AT caspermarkus alteredprofilesofcirculatingcytokinesinchronicliverdiseasesnafldhccimpactofthepnpla3i148mriskallele AT krawczykmarcin alteredprofilesofcirculatingcytokinesinchronicliverdiseasesnafldhccimpactofthepnpla3i148mriskallele AT lammertfrank alteredprofilesofcirculatingcytokinesinchronicliverdiseasesnafldhccimpactofthepnpla3i148mriskallele AT behrmanniris alteredprofilesofcirculatingcytokinesinchronicliverdiseasesnafldhccimpactofthepnpla3i148mriskallele |